Innate Pharma (IPHA) Other Operating Expenses (2019 - 2025)

Innate Pharma (IPHA) posted quarterly Other Operating Expenses of $1138.0 for Q4 2025, little changed on a QoQ basis from $1138.0 in Q2 2024.

Innate Pharma (IPHA) Other Operating Expenses (2019 - 2025) Analysis & Trends

Innate Pharma (IPHA) has reported Other Operating Expenses for 4 consecutive years, with $1138.0 the latest figure, recorded in Q4 2025.

Quarterly Other Operating Expenses changed N/A year-over-year to $1138.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2275.9 (up 100.0% YoY) and the FY2025 annual result came in at -$1138.0, changed N/A from the prior year.
Other Operating Expenses steadied at $1138.0 in Q4 2025 per IPHA's latest filing, from $1138.0 in the prior quarter.
Over the last five years, Other Operating Expenses for IPHA reached as high as $46.7 million in Q4 2022 and fell as low as $1138.0 in Q4 2025.
A 3-year average of $15.6 million and a median of $1138.0 in 2024 frame the typical range for Other Operating Expenses.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Innate Pharma	157.68 Mn	157.68 Mn	-

Download Data